Antiretroviral treatment in developing countries: the peril of neglecting private providers
Brugha, Rí.
BMJ 326(7403): 1382-1384
2003
ISSN/ISBN: 0959-8138 PMID: 12816829 DOI: 10.1136/bmj.326.7403.1382Document Number: 247864
This article discusses the risks of improper use of antiretroviral drugs, including development of resistant human immunodeficiency virus (HIV) strains. The control and regulation of antiretroviral drug dispensing, especially inc countries with high rates of HIV infection are highlighted.
Document emailed within 0-6 h
Related Documents
Mahase, E. 2023: UK aid funds "exploitative" private health providers in developing countries, Oxfam claims BMJ 381: 1468Berman, P.; Laura, R. 1996: The role of private providers in maternal and child health and family planning services in developing countries Health Policy and Planning 11(2): 142-155
Berman, P.; Laura, R. 1996: The role of private providers in maternal and child health and family planning services in developing countries Health Policy and Planning 11(2): 142-155
Orsi, F.; d'almeida, C. 2010: Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries Current Opinion in HIV and Aids 5(3): 237-241
Vergne, L.; Malonga-Mouellet, G.; Mistoul, I.; Mavoungou, R.; Mansaray, H.; Peeters, M.; Delaporte, E. 2002: Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries Journal of Acquired Immune Deficiency Syndromes 29(2): 165-168
Vergne, L.; Malonga-Mouellet, G.; Mistoul, I.; Mavoungou, R.; Mansaray, H.; Peeters, M.; Delaporte, E. 2002: Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries Journal of Acquired Immune Deficiency Syndromes 29(2): 165-168
Orsi, F.; d'almeida, C. 2010: Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries Current Opinion in HIV and Aids 5(3): 237-241
Nattrass, N.J. 2008: The (political) economics of antiretroviral treatment in developing countries Trends in Microbiology 16(12): 574-579
Shah, S.; Elmer, S.; Grady, C. 2009: Planning for Posttrial Access to Antiretroviral Treatment for Research Participants in Developing Countries American Journal of Public Health (1971) 99(9): 1556-1562
Tuboi, S.H.; Brinkhof, M.W.G.; Egger, M.; Stone, R.A.; Braitstein, P.; Nash, D.; Sprinz, E.; Dabis, Fçois.; Harrison, L.H.; Schechter, M. 2007: Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration Journal of Acquired Immune Deficiency Syndromes 45(1): 52-59
Tuboi, S.H.; Brinkhof, M.W.G.; Egger, M.; Stone, R.A.; Braitstein, P.; Nash, D.; Sprinz, E.; Dabis, Fçois.; Harrison, L.H.; Schechter, M. 2007: Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration Journal of Acquired Immune Deficiency Syndromes 45(1): 52-59
Waning, B.; Diedrichsen, E.; Moon, S. 2010: A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries Journal of the International Aids Society 13: 35
Johnson, D.; Cheng, X. 2014: The role of private health providers in HIV testing: analysis of data from 18 countries International Journal for Equity in Health 13: 36
Newell, J. 2002: The implications for TB control of the growth in numbers of private practitioners in developing countries Bulletin of the World Health Organization 80(10): 836-837
Hanson, K.; Berman, P. 1998: Private health care provision in developing countries: a preliminary analysis of levels and composition Health Policy and Planning 13(3): 195-211
Bertoméu-Sánchez, S.; Camos, D.; Estache, A. 2018: Do economic regulatory agencies matter to private-sector involvement in water utilities in developing countries? Utilities Policy 50: 153-163
Schoen Angerer, T. von; Wilson, D.; Ford, N.; Kasper, T. 2001: Access and activism: the ethics of providing antiretroviral therapy in developing countries AIDS 15(Suppl 5): S81-S90
Spira, S.C.; Wainberg, M.A. 2004: Jewish religious ethics mandate access to antiretroviral drugs in developing countries Journal of the International Association of Physicians in Aids Care 3(1): 7-11
Murray, C.J.L. 2015: Maximizing antiretroviral therapy in developing countries: the dual challenge of efficiency and quality JAMA 313(4): 359-360
Wang, T.; Hoag, S.W.; Eng, M.L.; Polli, J.; Pandit, N.S. 2015: Quality of antiretroviral and opportunistic infection medications dispensed from developing countries and Internet pharmacies Journal of Clinical Pharmacy and Therapeutics 40(1): 68-75